drugset / Trial / NCT05522868
SB17170 Phase 1 Clinical Trial in Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase 1 Open-label, multicenter, dose escalation, dose expansion study
Timeline
- Start
- 2022-10-17
- Primary completion
- 2027-06-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SB17170 | Unknown | 300 mg | Oral |
| Subject | SB17170 | Unknown | 600 mg | Oral |
| Subject | SB17170 | Unknown | 1000 mg | Oral |